Yanhong D. Deng

26 Yuancun Erheng Road
Guangzhou, 510655, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 219 publications

EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study.

EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 23, 2026

Correction to: Inhibition of the Type III Secretion System of Salmonella Enterica Serovar Typhimurium and Alleviation Pathogenicity Via Treatment with Xanthotoxol.

Correction to: Inhibition of the Type III Secretion System of Salmonella Enterica Serovar Typhimurium and Alleviation Pathogenicity Via Treatment with Xanthotoxol.

Journal: Current microbiology

Published: April 09, 2026

Degradation reshapes the toxic identity of polylactic acid microplastics through MSR1-dependent immune decoding in mouse kidney.

Degradation reshapes the toxic identity of polylactic acid microplastics through MSR1-dependent immune decoding in mouse kidney.

Journal: Particle and fibre toxicology

Published: April 03, 2026

VG161 oncolytic virus remodels the tumor microenvironment by expanding CD3+ macrophages and enhancing antitumor immunity.

VG161 oncolytic virus remodels the tumor microenvironment by expanding CD3+ macrophages and enhancing antitumor immunity.

Journal: Cancer letters

Published: March 17, 2026

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Journal: BMJ (Clinical research ed.)

Published: March 12, 2026

Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2).

Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2).

Journal: Med (New York, N.Y.)

Published: March 11, 2026

Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.

Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.

Journal: The Lancet. Oncology

Published: February 25, 2026

ASO Visual Abstract: Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients With Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trials.

ASO Visual Abstract: Clinical Benefit and Cost-Effectiveness of FOLFOX Versus LCCRT in Neoadjuvant Treatment for Patients With Locally Advanced Rectal Cancer: An Economic Analysis of the FOWARC and PROSPECT Trials.

Journal: Annals of surgical oncology

Published: February 13, 2026

PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer.

PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer.

Journal: Gut

Published: January 19, 2026

Cetuximab plus capecitabine every three weeks as first-line maintenance therapy for RAS/BRAF wild-type metastatic colorectal cancer: a phase Ib dose-escalation study.

Cetuximab plus capecitabine every three weeks as first-line maintenance therapy for RAS/BRAF wild-type metastatic colorectal cancer: a phase Ib dose-escalation study.

Journal: NPJ precision oncology

Published: January 09, 2026

Discovery of eucalyptus essential oil as a novel colistin adjuvant eradicate multidrug-resistant Gram-negative bacteria.

Discovery of eucalyptus essential oil as a novel colistin adjuvant eradicate multidrug-resistant Gram-negative bacteria.

Journal: Microbial pathogenesis

Published: November 30, 2025

Showing 1-12 of 219

Last Updated: 09/26/2026